Hormone receptor and HER2 status: The only predictive factors of response to neoadjuvant chemotherapy in breast cancer

References

• Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B et al.; National Surgical Adjuvant Breast and Bowel Project Protocol B-27. 2003. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. Journal of Clinical Oncology 21:4165–4174.
   PubMed Web of Science ®Google Scholar
• Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B et al. 2006. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer. National Surgical Adjuvant Breast and Bowel Project Protocol B-27. Journal of Clinical Oncology 24:2019–2027.
   PubMed Web of Science ®Google Scholar
• Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F et al. 2007. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clinical Cancer Research 13:2329–2334.
   PubMed Web of Science ®Google Scholar
• Chia S, Swain SM, Byrd DR, Mankoff DA. 2008. Locally advanced and inflammatory breast cancer. Journal of Clinical Oncology 26:786–790.
   PubMed Web of Science ®Google Scholar
• Cortazar P. 2012. Meta-analysis results from the Collaborative Trials in Neoadjuvant Breast Cancer. San Antonio Breast Cancer S1–11.
   Google Scholar
• DeWys WD. 1972. Studies correlating the growth rate of a tumor and its metastases and providing evidence for tumor-related systemic growth-retarding factors. Cancer Research 32:374–379.
   PubMed Web of Science ®Google Scholar
• Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L et al. 2011. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL. Breast Cancer Research and Treatment 132:1049–1062.
   PubMed Web of Science ®Google Scholar
• Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M et al. 2012. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL. Journal of Clinical Oncology 30:3242–3249.
   PubMed Web of Science ®Google Scholar
• Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER et al. 1998. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. Journal of Clinical Oncology 16:2672–2685.
   PubMed Web of Science ®Google Scholar
• Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S et al. 2010. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone in patients HER2-positive locally advanced breast cancer (The NOAH Trial): a randomised controlled superiority trial with a parallel Her2-negative cohort. Lancet 375:377–384.
   PubMed Web of Science ®Google Scholar
• Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G et al. 2008. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. Journal of Clinical Oncology 26:814–819.
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P et al. 2006. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. Journal of Clinical Oncology 24:1940–1949.
   PubMed Web of Science ®Google Scholar
• Ketcham AS, Wexler H, Mantel N. 1959. The effect of removal of a “primary” tumor on the development of spontaneous metastases. I. Development of a standardized experimental technique. Cancer Research 19:940–944.
   Web of Science ®Google Scholar
• Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA et al. 2008. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of Clinical Oncology 26: 1275–1281.
   PubMed Web of Science ®Google Scholar
• Mauri D, Pavlidis N, Loannidis JP. 2005. Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. Journal of the National Cancer Institute 97:188–194.
   PubMed Web of Science ®Google Scholar
• Meyers MO, Klauber-Demore N, Ollila DW, Amos KD, Moore DT, Drobish AA et al. 2011. Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. Annals of Surgical Oncology 18:2851–2857.
   PubMed Web of Science ®Google Scholar
• Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I et al. 2003. A new histological grading system to assess response of breast cancer to primary chemotherapy: prognostic significance and survival. Breast 12:320–327.
   PubMed Web of Science ®Google Scholar
• Rouzier R, Perou CM, Symmans WF. 2005. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clinical Cancer Research 11:5678–5685.
   PubMed Web of Science ®Google Scholar
• Schneeweiss A, Huober J, Sinn HP, von Fournier D, Rudlowski C, Beldermann F et al. 2004. Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study. European Journal of Cancer 40:2432–2438.
   PubMed Web of Science ®Google Scholar
• Symmans WF, Peintinger F, Hatzis C. 2007. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. Journal of Clinical Oncology 25:4414–4422.
   PubMed Web of Science ®Google Scholar
• Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H et al. 2010. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. Journal of Clinical Oncology 28:2024–2031.
   PubMed Web of Science ®Google Scholar
• Van der Hage JA, Van de Velde CJ, Julie JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. 2001. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902. Journal of Clinical Oncology 19:4224–4237.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA et al. 2012. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. Journal of Clinical Oncology 30: 1796–1799.
   PubMed Web of Science ®Google Scholar
• Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. 2001. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. Journal of the National Cancer Institute. Monographs. 30:96–102.
   PubMedGoogle Scholar